Blueprint appoints Charles Rowland to board
This article was originally published in Scrip
Blueprint Medicines, a company developing kinase drugs to treat patients with genomically defined diseases, has named Charles A Rowland Jr to its board of directors. Mr Rowland most recently served as vice-president and chief financial officer of ViroPharma, a global biopharmaceutical company. Before joining ViroPharma in 2008, Mr Rowland was executive vice-president and CFO, as well as interim co-CEO, for Endo Pharmaceuticals.
You may also be interested in...
In an exclusive interview, Barbara Lueckel, global head of research technologies at Roche Pharma Partnering, talks about the rationale behind the 2020 deals with Bicycle Therapeutics and Nimble Therapeutics. She gives insight into how deal makers are shifting gears to make deals happen in the challenging environment of the global coronavirus pandemic.
As the COVID-19 pandemic escalates, companies across the world are preparing to roll out commercial test kits for the detection of SARS-CoV-2.
Biopharmaceutical companies doubled-down on rare disease treatments during the last five years, thanks to a potent combination of scientific discovery and appealing business incentives.